MAP Pharma’s mixed IPO reception
See our story about the IPO of this Mountain View, Calif., specialty pharma at VentureBeat Life Sciences.
Next Story: Ontario pension buys proxy advisory firm, Glass Lewis, for $46M
Previous Story: IPO roundup: MAP Pharma’s mixed reception, other recent filings
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.